[1] Rothenstein J, Cleary SP, Pond GR, et al.Neuroendorine tumors of the gastrointestinal tract:adecade of experience at the Princess Margaret Hospital[J]. Am J Clin Oncol, 2008, 31(1): 64-70.
[2] Yao JC, Hassan M, Phan A, et al.One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States[J]. J Clin.Oncol, 2008, 26(18): 3063-3072.
[3] Eltawil KM, Gustafsson BI, Kidd M, Modlin IM.Neuroen-docfine tumors of the gallbladder: all evaluation and reassessment of management strategy[J]. J Clin Gastroenter, 2010, 44(44): 687-695.
[4] Kim D, Seo H, Lee JY, et at. Curative resection of combined neuroendoerine carcinoma and adenocarcinoma of the gallbladder[J]. Tumori, 2011, 97(6): 815-818.
[5] Inoue D, Ozaka M, Muramatsu Y, et al.Neuroendocrine gallbladder cancer treated with cisplatin plus irinotecan;a case report[J]. Gan To Kagaku Ryoho, 2014, 41(6): 765-767.
[6] Okuyamy Y, Fukui A, Enoki Y, et al.A large cell neuroendocrine carcinoma of the gall bladder; diagnosis with 18FDG-PET/CT-guided biliary cytology and treatment with combined chemotherapy achieved a long-term stable condition[J]. Jpn J Clin Oncol, 2013, 43(5): 571-574.
[7] Pavel ME, Hassler G, Baum U, et al.Circulating levels of angio-genic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas[J]. Clin Endocrinol, 2005, 62(4): 434-443.
[8] Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 501-513.
[9] Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancre-atic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 514-523. |
